CHP
CLVS

Castle Hook Partners’s Clovis Oncology, Inc. CLVS Stock Holding History

Castle Hook Partners’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-217,447
Closed -$14.8M – 76
2017
Q4 		$14.8M Buy
217,447
+65,500
+43% +$4.58M 0.74% 33
2017
Q3 		$12.5M Buy
+151,947
New +$12M 0.41% 40

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Castle Hook Partners's CLVS Position: Q1 2018 in Review

Castle Hook Partners sold out of Clovis Oncology, Inc. (CLVS) in Q1 2018, closing a stake of 217,447 shares — an estimated $14.8M sold.

Castle Hook Partners first reported a position in CLVS in Q3 2017 and held it in 2 quarters. The position peaked at $14.8M in Q4 2017. 229 funds tracked by Wall St. Rank hold CLVS as of Q1 2018.

  • Castle Hook Partners reported no remaining Clovis Oncology, Inc. position as of Q1 2018 after selling out during the quarter.
  • Castle Hook Partners sold 217,447 Clovis Oncology, Inc. shares in Q1 2018, an estimated $14.8M.
  • Castle Hook Partners first reported a position in Clovis Oncology, Inc. in Q3 2017 and held it in 2 quarters.
  • Castle Hook Partners's Clovis Oncology, Inc. position peaked at $14.8M in Q4 2017.
  • 229 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2018.

Based on Castle Hook Partners's 13F filing for Q1 2018, filed 15 May 2018.